Hürthle cell neoplasm: Difference between revisions
m →Clinical significance: Caps or other small fixes. using AWB |
Citation bot (talk | contribs) Alter: pages. Add: authors 1-1. Removed proxy/dead URL that duplicated identifier. Removed parameters. Formatted dashes. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Headbomb | #UCB_toolbar |
||
| (18 intermediate revisions by 10 users not shown) | |||
| Line 1: | Line 1: | ||
{{Infobox medical condition (new) |
|||
Hürthle Cell adenoma is a rare condition, often seen in women between the ages of seventy and eighty years old. This adenoma is often characterized by a mass of Hürthle cells. This mass is mostly benign, but may be malignant. If the mass is malignant, the mass is referred as a Follicular Thyroid Cancer or a Hürthle Cell Carcinoma.<ref name=":0">{{Cite web|title = Thyroid Cancer: About Thyroid Cancer {{!}} Memorial Sloan Kettering Cancer Center|url = https://www.mskcc.org/cancer-care/types/thyroid/about-thyroid|website = www.mskcc.org|accessdate = 2015-11-23}}</ref> |
|||
| name = {{PAGENAME}} |
|||
| synonyms = |
|||
| image = Histopathology of a Hürthle cell adenoma.jpg |
|||
| width = |
|||
| alt = |
|||
| caption = Histopathology of a Hürthle cell adenoma |
|||
| pronounce = |
|||
| field = oncology |
|||
| symptoms = |
|||
| complications = |
|||
| onset = |
|||
| duration = |
|||
| types = |
|||
| causes = |
|||
| risks = |
|||
| diagnosis = |
|||
| differential = |
|||
| prevention = |
|||
| treatment = |
|||
| medication = |
|||
| prognosis = |
|||
| frequency = |
|||
| deaths = |
|||
}} |
|||
[[File:Pie chart of relative incidences of thyroid cancers.png|thumb|Relative incidences of malignant thyroid tumors, with Hürthle cell carcinoma near top right.]] |
|||
'''Hürthle cell neoplasm''' is a rare tumor of the [[thyroid]], typically seen in women between the ages of 70 and 80 years old. When benign, it is called a '''Hürthle cell adenoma''', and when malignant it is called a '''Hürthle cell carcinoma'''. Hürthle cell adenoma is characterized by a mass of benign [[Hürthle cell]]s (Askanazy cells).<ref name=":0">{{Cite web|title = Thyroid Cancer: About Thyroid Cancer {{!}} Memorial Sloan Kettering Cancer Center|url = https://www.mskcc.org/cancer-care/types/thyroid/about-thyroid|website = www.mskcc.org|access-date = 2015-11-23}}</ref> Typically such a mass is removed because it is not easy to predict whether it will [[malignant transformation|transform]] into the [[cancer|malignant]] counterpart of Hürthle cell carcinoma, which is a subtype of [[follicular thyroid cancer]].<ref name="pmid_25810698">{{Citation |last1=Ristevska |first1=N |last2=Stojanoski |first2=S |last3=Gjorceva |first3=DP |year=2015 |title=Appearance of Hürthle cell carcinoma soon after surgical extirpation of Hürthle cell adenoma and follicular adenoma of the thyroid gland |journal=Radiol Oncol |volume=49 |issue=1 |pages=26–31 |pmid=25810698 |pmc=4362603 |doi=10.2478/raon-2014-0047 |postscript=.|title-link=surgical extirpation }}</ref><ref name="pmid_9697901">{{Citation |last=Wasvary |first=H |display-authors=etal |year=1998 |title=Unilateral lobectomy for Hürthle cell adenoma |journal=Am Surg |volume=64 |issue=8 |pages=729–732 |pmid=9697901 |postscript=.}}</ref> |
|||
== |
== Histology == |
||
* Histology |
|||
* Clinical Significance |
|||
* History |
|||
* Treatment |
|||
| ⚫ | |||
=== Histology === |
|||
[[File:Advantages-and-disadvantages-of-3D-ultrasound-of-thyroid-nodules-including-thin-slice-volume-1756-6614-4-1-S1.ogv|thumb|Hürthle Cell Adenoma nodule observed in 3D image of Thyroid]] |
[[File:Advantages-and-disadvantages-of-3D-ultrasound-of-thyroid-nodules-including-thin-slice-volume-1756-6614-4-1-S1.ogv|thumb|Hürthle Cell Adenoma nodule observed in 3D image of Thyroid]] |
||
Hürthle cells are characterized as enlarged epithelial |
Hürthle cells are characterized as enlarged [[epithelium|epithelial cell]]s. These cells, when [[staining|stained]] with [[H&E stain|hematoxylin-eosin]] show as [[pink]]. This is due to the abundant [[mitochondrion|mitochondria]] and granular [[eosinophilic]] matter within the cells' [[cytoplasm]]. These cells are often found in the [[thyroid]]. The thyroid is a butterfly-shaped organ, responsible for producing various [[hormone]]s for [[metabolism]]. These cells are often benign, but they can be malignant and [[metastasis|metastasize]]. Hürthle cells are resistant to radiation, but can be treated using [[isotopes of iodine#Iodine-131|radioactive iodine treatment]].<ref>{{Cite web|title = Hurthle Cell Adenoma|url = http://www.knowcancer.com/oncology/hurthle-cell-adenoma/|website = www.knowcancer.com|access-date = 2015-11-23}}</ref> |
||
==Diagnosis== |
|||
===Clinical significance=== |
|||
This mass can be detected and removed before transformation and metastasis. The tumor is often detected by imaging such as ultrasound. The location and size of the tumor may cause pressure and pain to the patient. But often the tumor goes undetected. After detection, the mass is tested using an invasive [[fine-needle aspiration biopsy]].<ref>{{Cite web|title = Follicular and Hurthle Cell Thyroid Cancer {{!}} Columbia University Department of Surgery|url = http://columbiasurgery.org/conditions-and-treatments/follicular-and-hurthle-cell-thyroid-cancer|website = columbiasurgery.org|access-date = 2015-11-23}}</ref> |
|||
Hürthle cell adenoma is the benign analogue of Hürthle cell carcinoma. This adenoma is extremely rare; when it occurs, it usually occurs in women. Often the adenoma is harmless but is removed after detection because its future course cannot be trusted.<ref name="pmid_25810698"/><ref name="pmid_9697901"/> |
|||
=== |
===Cytopathology=== |
||
[[File:Cytopathology suspicious for Hürthle cell neoplasm, annotated.png|thumb|350px|Cytopathology suspicious for Hürthle cell neoplasm ([[Bethesda category]] IV, rather than normal or hyperplastic Hürthle cells), Pap stain.<ref>Image by Mikael Häggström, MD. References for findings:<br>- {{cite web|url=https://www.pathologyoutlines.com/topic/thyroidhurthlecellneoplasm.html|title=Hürthle cell neoplasm|website=Pathology Outlines|author=Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D.}} Last author update: 7 May 2020. Last staff update: 12 May 2022<br>- {{cite journal| author=Shawky M, Sakr M| title=Hurthle Cell Lesion: Controversies, Challenges, and Debates. | journal=Indian J Surg | year= 2016 | volume= 78 | issue= 1 | pages= 41–8 | pmid=27186039 | doi=10.1007/s12262-015-1381-x | pmc=4848220 }}</ref>]] |
|||
| ⚫ | |||
Cytopathology cannot distinguish Hürthle cell adenoma from Hürthle cell carcinoma, which requires histopathologic sections to see transcapsular or vascular invasion. Hürthle cell hyperplasia (as seen in Hashimoto's thyroiditis) may show moderate variation in nuclear sizes and prominent nucleoli, but further findings favoring Hürthle cell neoplasm include a large number of Hürthle cells, and discohesiveness.<ref>- {{cite web|url=https://www.pathologyoutlines.com/topic/thyroidhurthlecellneoplasm.html|title=Hürthle cell neoplasm|website=Pathology Outlines|author=Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D.}} Last author update: 7 May 2020. Last staff update: 12 May 2022<br>- {{cite journal| author=Shawky M, Sakr M| title=Hurthle Cell Lesion: Controversies, Challenges, and Debates. | journal=Indian J Surg | year= 2016 | volume= 78 | issue= 1 | pages= 41–8 | pmid=27186039 | doi=10.1007/s12262-015-1381-x | pmc=4848220 }}</ref> |
|||
== Treatment == |
|||
There are three main treatments for Hürthle |
There are three main treatments for Hürthle cell adenomas. Once the adenoma is detected most often the nodules removed to prevent the cells from later metastisizing.<ref name="pmid_25810698"/><ref name="pmid_9697901"/> A total [[thyroidectomy]] is often performed, this results in a complete removal of the thyroid. Some patients may only have half of their thyroid removed, this is known as a thyroid [[lobectomy]]. Another treatment option includes pharmacological suppression of [[thyroid hormone]]. The thyroid gland is responsible for producing the thyroid hormones triiodothyronine (T3) and thyroxine (T4). Patients with suppressed thyroid function often require oral thyroid replacement (e.g. levothyroxine) in order to maintain normal thyroid hormone levels. The final treatment option is RAI ablation (radioactive iodine ablation). This treatment option is used to destroy infected thyroid cells after total thyroidectomy. This treatment does not change prognosis of disease, but will diminish the recurrence rate. Also, Hürthle cells do not respond well to RAI. However, often doctors suggest this treatment to patients with Hürthle cell adenoma and Hürthle cell carcinoma because some Hürthle cells will respond and it will kill remaining tissue.<ref name=":0" /> |
||
== History == |
|||
| ⚫ | |||
| ⚫ | |||
{{reflist}} |
{{reflist}} |
||
| Line 33: | Line 57: | ||
[[Category:Thyroid]] |
[[Category:Thyroid]] |
||
[[Category:Articles containing video clips]] |
[[Category:Articles containing video clips]] |
||
{{cell-biology-stub}} |
|||
Latest revision as of 02:14, 4 December 2022
| Hürthle cell neoplasm | |
|---|---|
 | |
| Histopathology of a Hürthle cell adenoma | |
| Specialty | Oncology |
Hürthle cell neoplasm is a rare tumor of the thyroid, typically seen in women between the ages of 70 and 80 years old. When benign, it is called a Hürthle cell adenoma, and when malignant it is called a Hürthle cell carcinoma. Hürthle cell adenoma is characterized by a mass of benign Hürthle cells (Askanazy cells).[1] Typically such a mass is removed because it is not easy to predict whether it will transform into the malignant counterpart of Hürthle cell carcinoma, which is a subtype of follicular thyroid cancer.[2][3]
Histology
[edit]Hürthle cells are characterized as enlarged epithelial cells. These cells, when stained with hematoxylin-eosin show as pink. This is due to the abundant mitochondria and granular eosinophilic matter within the cells' cytoplasm. These cells are often found in the thyroid. The thyroid is a butterfly-shaped organ, responsible for producing various hormones for metabolism. These cells are often benign, but they can be malignant and metastasize. Hürthle cells are resistant to radiation, but can be treated using radioactive iodine treatment.[4]
Diagnosis
[edit]This mass can be detected and removed before transformation and metastasis. The tumor is often detected by imaging such as ultrasound. The location and size of the tumor may cause pressure and pain to the patient. But often the tumor goes undetected. After detection, the mass is tested using an invasive fine-needle aspiration biopsy.[5] Hürthle cell adenoma is the benign analogue of Hürthle cell carcinoma. This adenoma is extremely rare; when it occurs, it usually occurs in women. Often the adenoma is harmless but is removed after detection because its future course cannot be trusted.[2][3]
Cytopathology
[edit]
Cytopathology cannot distinguish Hürthle cell adenoma from Hürthle cell carcinoma, which requires histopathologic sections to see transcapsular or vascular invasion. Hürthle cell hyperplasia (as seen in Hashimoto's thyroiditis) may show moderate variation in nuclear sizes and prominent nucleoli, but further findings favoring Hürthle cell neoplasm include a large number of Hürthle cells, and discohesiveness.[7]
Treatment
[edit]There are three main treatments for Hürthle cell adenomas. Once the adenoma is detected most often the nodules removed to prevent the cells from later metastisizing.[2][3] A total thyroidectomy is often performed, this results in a complete removal of the thyroid. Some patients may only have half of their thyroid removed, this is known as a thyroid lobectomy. Another treatment option includes pharmacological suppression of thyroid hormone. The thyroid gland is responsible for producing the thyroid hormones triiodothyronine (T3) and thyroxine (T4). Patients with suppressed thyroid function often require oral thyroid replacement (e.g. levothyroxine) in order to maintain normal thyroid hormone levels. The final treatment option is RAI ablation (radioactive iodine ablation). This treatment option is used to destroy infected thyroid cells after total thyroidectomy. This treatment does not change prognosis of disease, but will diminish the recurrence rate. Also, Hürthle cells do not respond well to RAI. However, often doctors suggest this treatment to patients with Hürthle cell adenoma and Hürthle cell carcinoma because some Hürthle cells will respond and it will kill remaining tissue.[1]
History
[edit]The first Hürthle cell adenoma was discovered by Dr James Ewing in 1928. Hürthle cells were discovered in the 1890s and are named after Karl Hürthle and Max Askanazy.
References
[edit]- ^ a b "Thyroid Cancer: About Thyroid Cancer | Memorial Sloan Kettering Cancer Center". www.mskcc.org. Retrieved 2015-11-23.
- ^ a b c Ristevska, N; Stojanoski, S; Gjorceva, DP (2015), "Appearance of Hürthle cell carcinoma soon after surgical extirpation of Hürthle cell adenoma and follicular adenoma of the thyroid gland", Radiol Oncol, 49 (1): 26–31, doi:10.2478/raon-2014-0047, PMC 4362603, PMID 25810698.
- ^ a b c Wasvary, H; et al. (1998), "Unilateral lobectomy for Hürthle cell adenoma", Am Surg, 64 (8): 729–732, PMID 9697901.
- ^ "Hurthle Cell Adenoma". www.knowcancer.com. Retrieved 2015-11-23.
- ^ "Follicular and Hurthle Cell Thyroid Cancer | Columbia University Department of Surgery". columbiasurgery.org. Retrieved 2015-11-23.
- ^ Image by Mikael Häggström, MD. References for findings:
- Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D. "Hürthle cell neoplasm". Pathology Outlines.{{cite web}}: CS1 maint: multiple names: authors list (link) Last author update: 7 May 2020. Last staff update: 12 May 2022
- Shawky M, Sakr M (2016). "Hurthle Cell Lesion: Controversies, Challenges, and Debates". Indian J Surg. 78 (1): 41–8. doi:10.1007/s12262-015-1381-x. PMC 4848220. PMID 27186039. - ^ - Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D. "Hürthle cell neoplasm". Pathology Outlines.
{{cite web}}: CS1 maint: multiple names: authors list (link) Last author update: 7 May 2020. Last staff update: 12 May 2022
- Shawky M, Sakr M (2016). "Hurthle Cell Lesion: Controversies, Challenges, and Debates". Indian J Surg. 78 (1): 41–8. doi:10.1007/s12262-015-1381-x. PMC 4848220. PMID 27186039.
External links
[edit]